William W.L. Wong

Has grant

Associate Professor

University of Waterloo
Country flag
Canada

Research Interests

Explore related searches

Contact this professor

LinkedIn
ORCID
Google Scholar

About

William W.L. Wong is an Associate Professor at the University of Waterloo, Canada. His research areas primarily focus on healthcare economics, particularly related to hepatitis B and C, including their prevalence, treatment costs, and patient outcomes. His recent publications examine the effectiveness and impact of antiviral therapies and public health strategies in Canadian healthcare settings.

Recent Grants

Grant: Close

Improvements in quality of life, health utility, cost, and return to work for lymphoma patients after chimeric antigen receptor T- cells therapy in a real-world setting

Open Date: 2022-03-01

Close Date: 2023-02-28

Grant: Close

Estimating chronic hepatitis B prevalence and the undiagnosed proportion in Canada using health administrative data

Open Date: 2021-11-01

Close Date: 2022-10-31

Grant: Close

Understanding the treatment benefits of chimeric antigen receptor T-cells for lymphoma: quality of life, health utility, cost, and return to work

Open Date: 2021-03-01

Close Date: 2022-02-28

Grant: Close

The Response of Provincial Health Systems to COVID-19: Service Provision and Costs Across Health Sectors, First Nations and other populations

Open Date: 2020-06-01

Close Date: 2020-09-30

Grant: Close

Real-world effectiveness and cost-effectiveness of novel hepatitis C treatments

Open Date: 2020-04-01

Close Date: 2022-03-31

Articles (15)

Hepatitis C Attributable Healthcare Costs and Mortality among Immigrants: A Population-Based Matched Cohort Study

Background. Data on the economic burden of chronic hepatitis C (CHC) among immigrants are limited. Our objective was to estimate the CHC-attributable mortality and healthcare costs among immigrants in Ontario, Canada. Methods. We conducted a population-based matched cohort study among immigrants diagnosed with CHC between May 31, 2003, and December 31, 2018, using linked health administrative data. Immigrants with CHC (exposed) were matched 1 : 1 to immigrants without CHC (unexposed) using a combination of hard (index date, sex, and age) and propensity-score matching. Net costs (2020 Canadian dollars) collected from the healthcare payer perspective were calculated using a phase-of-care approach and used to estimate long-term costs adjusted for survival. Results. We matched 5,575 exposed individuals with unexposed controls, achieving a balanced match. The mean age was 47 years, and 52% was male. On average, 10.5% of exposed and 3.5% of unexposed individuals died 15 years postindex (relative risk = 2.9; 95% confidence interval (CI): 2.6–3.5). The net 30-day costs per person were $88 (95% CI: 55 to 122) for the prediagnosis, $324 (95% CI: 291 to 356) for the initial phase, $1,016 (95% CI: 900 to 1,132) for the late phase, and $975 (95% CI: −25 to 1,974) for the terminal phase. The mean net healthcare cost adjusted for survival at 15 years was $90,448. Conclusions. Compared to unexposed immigrants, immigrants infected with CHC have higher mortality rates and greater healthcare costs. These findings will support the planning of HCV elimination efforts among key risk groups in the province.

Year:

2024

Collaborators (6)

Mhd. Wasem Alsabbagh

Associate Professor

University of Waterloo Faculty of Science

CANADA

Jennifer D Walker

Associate Professor

McMaster University

CANADA

Andrew P Costa

McMaster University

CANADA

Mina Tadrous

University of Toronto

UNITED STATES

Naveed Janjua

Clinical Professor

The University of British Columbia

CANADA

Beate Sander

University Health Network

CANADA
Social connections

How do I reach out?

Sign in for free to see their profile details and contact information.

Meet Kite AI